Financial Ratios

OXYGENTA PHARMACEUTICAL LTD.

NSE : NABSE : 524636ISIN CODE : INE102E01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE29.000.79 (+2.8 %)
PREV CLOSE ( ) 28.21
OPEN PRICE ( ) 28.21
BID PRICE (QTY) 28.10 (434)
OFFER PRICE (QTY) 28.98 (3)
VOLUME 8531
TODAY'S LOW / HIGH ( )28.02 29.60
52 WK LOW / HIGH ( ) 25.0252.27
NSE
This Company is not listed in NSE
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)-8.15-0.432.87-5.67-3.19
   CEPS(Rs)-6.700.694.04-4.69-2.19
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)-32.53-24.38-37.27-40.14-34.47
   Tax Rate(%)-1.74-24.756.812.586.84
Margin Ratios
   Core EBITDA Margin(%)-22.972.447.39-57.36-9.96
   EBIT Margin(%)-31.900.729.47-35.34-13.39
   Pre Tax Margin(%)-36.70-0.816.04-43.31-17.03
   PAT Margin (%)-37.34-1.015.63-42.20-15.87
   Cash Profit Margin (%)-30.721.627.93-34.92-10.90
Performance Ratios
   ROA(%)-27.09-1.8811.16-29.10-17.07
   ROE(%)0.000.000.000.000.00
   ROCE(%)-50.313.180.000.000.00
   Asset Turnover(x)0.731.861.980.691.08
   Sales/Fixed Asset(x)0.751.791.850.550.84
   Working Capital/Sales(x)-6.4440.46-33.50-1.51-2.59
Efficiency Ratios
   Fixed Capital/Sales(x)1.340.560.541.811.18
   Receivable days69.129.617.1312.498.84
   Inventory Days111.8358.4957.41127.5361.29
   Payable days234.9178.25109.07199.77223.72
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)-5.4634.820.000.000.00
   Price/Book(x)-1.13-0.990.000.000.00
   Yield(%)0.000.00
   EV/Net Sales(x)3.871.421.112.701.59
   EV/Core EBITDA(x)-16.8858.1714.65-4.72-18.82
   EV/EBIT(x)-12.13197.7311.70-7.63-11.84
   EV/CE(x)2.212.761.701.991.54
   M Cap / Sales1.680.560.000.000.00
Growth Ratio
   Net Sales Growth(%)-48.8016.33279.30-33.1259.35
   Core EBITDA Growth(%)-579.49-62.36150.21-353.2634.44
   EBIT Growth(%)-2369.42-91.16201.63-76.4723.20
   PAT Growth(%)-1795.44-120.84150.62-77.8728.14
   EPS Growth(%)-1795.28-114.97150.62-77.8728.14
Financial Stability Ratios
   Total Debt/Equity(x)-1.47-1.51-1.26-0.66-0.64
   Current Ratio(x)0.841.190.910.430.53
   Quick Ratio(x)0.450.280.220.160.21
   Interest Cover(x)-6.650.472.76-4.43-3.68
   Total Debt/Mcap(x)1.311.53

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.